Reports

      Effects of aerosol from the Tobacco Heating System (THS) on human organotypic cultures of the aerodigestive tract

      Zanetti, F.; Iskandar, A.

      Published on
      Sep 8, 2021
      Link to publication
      Topic
      Summary

      Cigarette smoking is responsible for a multitude of health risks and is one of the major modifiable risk factors for many smoking-related diseases. Tobacco Heating System (THS) is an electronic device, which heats tobacco instead of burning it. The THS aerosol has a different chemical composition to cigarette smoke, with its levels of harmful and potentially harmful constituents reduced on average by 90-95%. Advances in tissue engineering have enabled the development of sophisticated, three-dimensional organotypic culture systems that closely resemble human physiology. In several recent studies, buccal, gingival, nasal, bronchial, and small airway human epithelial organotypic cultures were exposed to aerosol from the THS and cigarette smoke. Standard toxicological assays were combined with network-based systems toxicology analyses to identify otherwise undetectable cellular-level effects. The results showed that the THS aerosol has a minimal biological impact on cells in comparison to cigarette smoke.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.